An S&P 500 ETF With Minimal Fees to Hold for the Long Term
In an environment where geopolitical tensions and tariff threats continue to worry investors and weigh on individual stocks, one safe way for investors to invest in the overall markets is to just track the S&P 500 index. And an easy way to do to that is through the iShares Core S&P 500 ETF (NYSE Arca:IVV). The exchange-traded fund (ETF) seeks to track the investment results of an index composed of large‑cap U.S. stocks, giving investors exposure to established businesses. It holds around 500 companies, mirroring the composition of the S&P 500 index, and it yields around 1.3%. The top holdings reflect the dominance of large U.S. technology and consumer companies. Nvidia (NASDAQ:NVDA), Microsoft (NASDAQ:MSFT), and Apple (NASDAQ:AAPL) are among the top stocks in the ETF. One of the most attractive features of the fund are its minimal costs, as it has an expense ratio of just 0.03%. This allows investors to not have to worry about fees chipping away at their returns in the long run. Historically, this has been a top growth fund to invest in, as it has risen by more than 90% in five years. And over the past 12 months, it’s up by 16%. For investors worried about individual stocks and market conditions, the IVV ETF provides a straightforward way to benefit from the market’s long-term growth. While there may be tough years along the way, it’s a good, no-nonsense way to invest in stocks and keep your overall risk low over the long term. The ETF is a great option as it offers a mix of stability, dividends, and growth.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


